How Blinatumomab’s Mechanism Shapes Cytokine Release Syndrome Risk in ALL Care

Blinatumomab’s (Blincyto; Amgen) unique role as a bispecific T-cell engager brings meaningful advances to acute lymphoblastic leukemia (ALL) care—but it also introduces a distinct cytokine release syndrome (CRS) profile that clinicians must navigate thoughtfully. In this interview, Allison Yang, PharmD, a PGY2 oncology pharmacy resident at Atrium Health Wake Forest Baptist, outlines how the drug’s mechanism heightens immunologic activation, why disease burden remains the strongest predictor of CRS, and how pharmacists shape safe management from inpatient initiation through outpatient continuation.

Q: Blinatumomab’s mechanism as a bispecific T-cell engager (BiTE) antibody is somewhat unique compared to other immunotherapies. How does that mechanism specifically predispose patients to cytokine release syndrome (CRS), and how does the incidence and severity of CRS with blinatumomab compare to what we see with chimeric antigen receptor T-cell (CAR T) therapy or traditional monoclonal antibodies?

Allison Yang, PharmD: Yeah. So blinatumomab is a CD19 and CD3 T-cell engager, so it works like a bispecific antibody. It does predispose patients to CRS, as all our BiTE therapies do increase our immunologic response. Because of that, patients are at high risk for CRS. Compared to CAR T therapy, blinatumomab does have much lower rates of CRS and neurotoxicity involved, but it is still something that we look out for in everyone.

Q: Are there patient-specific or disease-specific factors—such as disease burden, prior treatment history, or measurable residual disease (MRD) status—that meaningfully predict which patients with acute lymphoblastic leukemia (ALL) are most likely to develop CRS during blinatumomab therapy?

Yang: So my research project was actually looking and seeing if there is a difference in disease characteristics that patients might experience—whether they have an increased experience in CRS. One of the things that we were able to try to figure out is: if there is more minimal residual disease, is there going to be higher occurrences of CRS? What we were able to see is that there are increased rates of CRS with our patients who are in more of a relapsed or refractory phase, or if they do have higher disease burden during our consolidation phase when they are getting treatment initially. So I would say definitely disease burden is the biggest marker for patients who might have a higher risk for or higher occurrences of CRS.

Q: CRS can be difficult to distinguish from infection or disease progression, especially in an already immunocompromised ALL population. What are the clinical and laboratory red flags that should prompt a pharmacist or clinician to escalate concern for CRS, and how does grading severity shape the management response?

Yang: Yeah. So the grading severity for CRS is based off of literature that the transplant field deals with when they are dealing with CAR T therapies, and so we extrapolate from their grading scale. We use the American Society for Transplantation and Cellular Therapy grading scale for CRS and immune effector cell-associated neurotoxicity syndrome (ICANS). Each category specifies if a patient experiences a fever or has lower blood pressure—so if they are hypotensive—or if they have any shortness of breath. Depending on the severity of their CRS, it could result in patients being on vasopressors as well as extra oxygen support. Therefore, that clues us into potentially trying to coordinate care with our ICU team so that we are able to facilitate an easy transition from the floor over to the ICU.

Q: Beyond tocilizumab and corticosteroids, what does optimal pharmacist-driven management of blinatumomab-associated CRS look like, from premedication strategies and infusion monitoring protocols to dose-interruption decisions?

Yang: Yeah. I think the biggest role that pharmacists play when it comes to blinatumomab is definitely when we are trying to reinitiate after a patient has experienced a high enough grade of either CRS or ICANS, which is our neurotoxicity that we see with blinatumomab. Most of the time, the pharmacists are really involved in helping the physicians decide at what time point is a good time to resume blinatumomab. One thing to always keep in mind is that when we resume blinatumomab, patients are potentially at risk for CRS again. We always have to make sure in our treatment plans that we build in our dexamethasone premedication in case the blinatumomab has been held for longer than what we would like. So that is our biggest role as pharmacists—helping decide what dose to resume blinatumomab and then making sure that we are premedicating with the dexamethasone prior to resuming.

Q: Blinatumomab is administered as a continuous intravenous (IV) infusion over weeks, which creates unique monitoring demands. How has your institution adapted workflows or patient education to catch CRS events that may occur outside of a clinical setting, particularly for patients on outpatient therapy?

Yang: Yeah. I think because we are admitting patients during their first cycle, when they are at highest risk for CRS, the biggest thing that we will do in clinic is make sure that we are communicating to patients that these are the things that we are looking out for with CRS while they are inpatient, so that they have an understanding of what potential side effects or interventions we are going to make inpatient. Usually by the time we are comfortable sending patients to outpatient for blinatumomab administration is around cycle two or three. Because of that, a lot of times we will not see a reoccurrence of CRS once they resume blinatumomab for their next cycles. At Wake Forest, we will make sure that the patient understands that there is a lower risk for CRS, but we will definitely reinforce that these are the types of things to look out for if they ever do experience it, and to make sure that they call our clinic number—which is open 24/7—to facilitate an easy admission so that we can observe for those signs and symptoms.

Q: As blinatumomab moves into earlier lines of therapy and combination regimens, do you anticipate the CRS risk profile changing? Are there gaps in the current literature you would most like to see addressed in future research?

Yang: With blinatumomab now being pushed forward from the relapsed or refractory patient population into first-line therapy and consolidation, it is definitely something that we are trying to still figure out—whether there is higher risk with trying to introduce blinatumomab upfront versus later. As I mentioned before, with a higher disease burden or if they have been exposed to multiple lines of therapy in the past, they will have a higher risk for CRS. But I think with the push for blinatumomab to now be utilized in the first-line setting for newly diagnosed leukemia patients, we will still see relatively high risk rates of CRS, but I think that they are significantly lower than what we initially saw with our relapsed or refractory patient group.